| Document Date: 2008-12-05 08:30:11
Open Document File Size: 1,95 MBShare Result on Facebook
Company GLAXOSMITHKLINE / Glaxosmithkline plc / / Country United States / United Kingdom / / Event FDA Phase / / Facility Each bar / / IndustryTerm fixed dose combination product / inhaler devices / study protocol / / MedicalCondition OF ASTHMA / unsurpassed asthma / airway smooth muscle bronchoconstriction / Asthma Asthma / disease / inflammatory process / both inflammation / persistent asthma / inflammatory component / uncontrolled asthma / evidence-based asthma / inflammation / chronic inflammatory disorder / Asthma / / Organization American Lung Association / FDA / Medicines and Healthcare Products Regulatory Agency / Advisory Committee / / Position EXECUTIVE / physician / controller / / Product fluticasone propionate / theophylline / ADVAIR DISKUS / ICS medication / albuterol / SEREVENT / salmeterol / study drug / / RadioStation Baseline AM / / Technology study protocol / /
SocialTag |
GLAXOSMITHKLINE Sponsor Briefing Information ADVAIR DISKUS® (fluticasone propionate/salmeterol inhalation powder[removed]mcg, [removed]mcg and[removed]mcg